Research, Select, & Monitor Tuesday, September 22, 2020 4:27:16 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
InfuSystems Holdings Inc.$12.97$.09.70%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 InfuSystem Holdings, Inc. Reports Second Quarter 2019 Financial Results
   Wednesday, August 14, 2019 6:38:00 AM ET

“Increase of 20.2% in Revenue vs. Same Prior Year Period as First Phase of Market Share Gains Significantly Impact Net Revenues.”

MADISON HEIGHTS, Michigan, Aug. 14, 2019 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American LLC: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today reported financial results for the second quarter ended June 30, 2019.

Second Quarter Highlights:

  • Net revenues for the three and six months ended June 30, 2019 were $19.7 million and $37.9 million, respectively, a $3.3 million, or 20.2%, increase and $5.0 million, or 15.3%, increase, respectively, from the same prior year periods.
  • Net income for the quarter ended June 30, 2019 was $0.4 million compared to a net loss of $0.5 million for the same prior year period. Net loss year-to-date June 30, 2019 was $0.6 million compared to a net loss of $0.3 million year-to-date June 30, 2018.
  • Adjusted earnings before income taxes, depreciation, and amortization (“Adjusted EBITDA”) for the three and six months ended June 30, 2019 was $4.5 million and $7.6 million, respectively, a $1.4 million, or 42.6%, increase and $0.9 million, or 13.4%, increase, respectively, from the same prior year periods.
  • Cash flows provided by operating activities were $4.3 million year-to-date, a decrease of $0.5 million, or 10.9%, from the same prior year period, primarily due to a net increase in the change in accounts receivable of $2.9 million related to our growth.

Commenting on the second quarter, Richard DiIorio, chief executive officer of InfuSystem, said, “We are operating according to plan, and as discussed in prior periods, we are starting to see the impact of the market share gains in our oncology business that began last year with elastomerics and is continuing this year with electronic pumps. We are also benefiting from growth in our pain management and infusion products markets. In addition to the market share gains, we are continuing to execute on a multiyear upgrade in revenue cycle management practices.  Every additional dollar collected for services that have already been delivered is additive to revenue, earnings, EBITDA and cash flow.”

Mr. DiIorio continued, “I am, of course, pleased with our results in the first half of the year.  The first phase involves primarily the market share gains made last year from elastomerics.  In the second phase, we are completing the larger market share gains in electronic pumps resulting from our largest direct competitor changing its business model.  The financial impact from the second phase market share gains will be seen in our financial results for the second half of 2019 and the first half of 2020.” 

Mr. DiIorio concluded, “We continue to build the infrastructure to absorb this growth by adding strong talent to our already outstanding team, investing in our physical facilities and adding to and replenishing our already best-in-class fleet of electronic pumps. The benefits of these investments will not only enable our current growth, but we expect to contribute to long-term profitability and ongoing value creation for our shareholders.”

Conference Call
The Company will conduct a conference call for investors on Wednesday, August 14, 2019 at 9:00 a.m. Eastern Time to discuss second quarter 2019 results. The conference call may also include a discussion of Company developments, forward-looking statements and other material information about business and financial matters. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the investors section of the Company’s website at .  A replay of the call will be available by visiting for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10134095, through August 21, 2019.

Condensed Consolidated Financial Statements
Certain balances in the condensed consolidated financial statements for the quarter and year-to-date ended June 30, 2018 have been reclassified to be consistent with the quarter and year-to-date ended June 30, 2019 presentation in accordance with GAAP.

Non-GAAP Measures
This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring items that are not part of the normal course of business and that the Company’s management does not believe will have similar comparable year-over-year items or for non-operating items. A reconciliation of those measures to the most directly comparable GAAP measures is provided below.

About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. The Company’s stock is traded on the NYSE American LLC under the symbol INFU.

Forward-Looking Statements

The financial results in this press release reflect preliminary results, which are not final until the Company's Form 10-Q for the quarter ended June 30, 2019 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, future operating or financial performance. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Additional information about InfuSystem Holdings, Inc. is available at .



 As of
 June 30, December 31,
(in thousands, except share data) 2019   2018 
Current assets:   
  Cash and cash equivalents$  1,702  $  4,318 
  Accounts receivable, net   11,218     9,593 
  Inventories   2,742     2,254 
  Other current assets   1,368     1,372 
  Total current assets   17,030     17,537 
Medical equipment for sale or rental   1,927     1,601 
Medical equipment in rental service, net of accumulated depreciation   28,873     23,488 
Property & equipment, net of accumulated depreciation   1,539     1,445 
Intangible assets, net   17,616     19,865 
Operating lease right of use assets   5,182     -  
Other assets   194     137 
  Total assets$  72,361  $  64,073 
Current liabilities:   
  Accounts payable$  10,206  $  7,091 
  Current portion of long-term debt   6,084     4,903 
  Other current liabilities   4,244     2,796 
  Total current liabilities   20,534     14,790 
Long-term debt, net of current portion   27,478     28,842 
Deferred income taxes   76     -  
Operating lease liabilities, net of current portion   4,021     -  
  Total liabilities   52,109     43,632 
Stockholders’ equity:   
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued   -     - 
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and     
outstanding 23,237,703 and 19,719,214, respectively, as of June 30, 2019      
and 23,095,513 and 19,577,024, respectively, as of December 31, 2018   2     2 
Additional paid-in capital   83,557     83,167 
Retained deficit   (63,307)    (62,728)
Total stockholders’ equity   20,252     20,441 
  Total liabilities and stockholders’ equity$  72,361  $  64,073 
See accompanying notes to unaudited condensed consolidated financial statements.

 Three Months Ended Six Months Ended
(in thousands, except share and per share data)June 30 June 30
  2019   2018   2019   2018 
Net revenues$  19,723  $  16,415  $  37,916  $  32,898 
Cost of revenues   8,367     6,729     16,219     12,975 
Gross profit    11,356     9,686     21,697     19,923 
Selling, general and administrative expenses:       
Amortization of intangibles    1,124     1,165     2,249     2,352 
Selling and marketing    2,476     2,326     5,078     4,627 
General and administrative    6,785     6,399     13,819     12,560 
Total selling, general and administrative   10,385     9,890     21,146     19,539 
Operating income (loss)   971     (204)    551     384 
Other expense:       
Interest expense    (488)    (296)    (948)    (611)
Other (expense) income   (39)    1     (60)    (10)
Income (loss) before income taxes    444     (499)    (457)    (237)
Provision for income taxes   (63)    (6)    (122)    (64)
Net income (loss)$  381  $  (505) $  (579) $  (301)
Net income (loss) per share:       
Basic$  0.02  $  (0.02) $  (0.03) $  (0.02)
Diluted   0.02     (0.02)    (0.03)    (0.02)
Weighted average shares outstanding:       
Basic 19,708,422   22,703,415   19,644,590   22,751,318 
Diluted 20,583,434   22,703,415   19,644,590   22,751,318 
See accompanying notes to unaudited condensed consolidated financial statements.

 Six Months Ended 
 June 30 
(in thousands) 2019   2018  
Purchase of medical equipment, property and equipment (7,893)  (2,743) 
Proceeds from sale of medical equipment, property and equipment 1,333   1,720  
Principal payments on term loans, capital lease obligations and other financing (2,256)  (3,708) 
Cash proceeds from other financing 2,024    -   
Debt issuance costs (3)   -   
Common stock repurchased to satisfy statutory withholding on employee 
  stock based compensation plans (208)  (5) 
Common stock repurchased as part of Repurchase Program   -    (1,264) 
Cash proceeds from stock plans 68   46  
Net change in cash and cash equivalents  (2,616)  (1,108) 
Cash and cash equivalents, beginning of period  4,318   3,469  
Cash and cash equivalents, end of period $1,702  $2,361  
See accompanying notes to unaudited condensed consolidated financial statements.

 Three Months Ended Six Months Ended
  June 30
 June 30
(in thousands)  2019   2018   2019   2018 
GAAP net income (loss)$  381  $  (505) $  (579) $  (301)
  Interest expense   488     296     948     611 
  Income tax provision   63     6     122     64 
  Depreciation   1,896     1,625     3,676     3,253 
  Amortization   1,124     1,165     2,249     2,352 
Non-GAAP EBITDA$   3,952   $   2,587   $   6,416   $   5,979  
Stock compensation costs   284     265     530     391 
Early termination fees for capital leases   -      -      190     -  
Shareholder costs   -      147     -      147 
Exited facility costs   -      44     6     44 
Management reorganization/transition costs   -      90     45     137 
ASC 842 accounting principle change   108     -      108     -  
Certain other non-recurring costs   179     40     347     40 
Non-GAAP Adjusted EBITDA$   4,523   $   3,173   $   7,642   $   6,738  
GAAP Net Revenues$  19,723  $  16,415  $  37,916  $  32,898 
Non-GAAP Adjusted EBITDA Margin 22.9%   19.3%   20.2%   20.5% 

Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues.

CONTACT:    Joe Dorame, Joe Diaz & Robert Blum
  Lytham Partners, LLC


Source: InfuSystem Holdings Inc.

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.